MDMB-PINACA

The following information was compiled in February 2026 and is subject to change as new research is conducted and as new information becomes available:

Description: MDMB-PINACA is a synthetic cannabinoid bearing structural resemblance to other indazole-core synthetic cannabinoids (e.g., MDMB-4en-PINACA, 5F-MDMB-PINACA [also known as 5F-ADB]). MDMB-PINACA is a cannabinoid receptor agonist with higher potency and efficacy (CB₁: pEC₅₀=8.59±0.07, E_max=66%; CB₂: pEC₅₀=9.89±0.09, E_max=68%) compared to delta-9-THC (CB₁: pEC₅₀=7.47±0.16, E_max=51%; CB₂: pEC₅₀=6.62±0.25, E_max=21%).^1,2 MDMB-PINACA was first identified by our laboratory in January 2026 in a postmortem blood specimen originating from Louisiana and confirmed after acquiring standard reference material. MDMB-PINACA has since been detected in nine oral fluid specimens collected from New Orleans, LA, and has been identified alongside THC, cocaine, methamphetamine, fentanyl, and other synthetic cannabinoids and synthetic cannabinoid precursors (e.g., MDMB-4en-PINACA, MDMB-5Me-INACA, MDMB-INACA, 5F-ADB). MDMB-PINACA has not yet been identified in drug materials at the CFSRE. MDMB-PINACA is not currently scheduled in the United States.

Class:

Cannabinoid

Appearance:

Blood

Formula:

C20H29N3O3

MW:

359.5

[M+]:

359

[M+H]+:

360.2282

IUPAC:

3-methyl-N-[(1-pentyl-1H-indazol-3-yl)carbonyl]-valine methyl ester

Report Date:

February 17, 2026